Starry(SH:603520) Xin Lang Cai Jing·2025-11-07 05:56Group 1 - The core viewpoint of the news is that Zhejiang Sitaili Pharmaceutical Co., Ltd. has seen a significant increase in its stock price, with a rise of 5.33% to 11.06 CNY per share, and a total market capitalization of 4.849 billion CNY [1] - The company specializes in the production and sales of non-ionic iodine contrast agents and quinolone raw materials, with the contrast agent series accounting for 79.73% of its main business revenue [1] - The company was established on September 15, 1997, and went public on March 9, 2016 [1] Group 2 - Xiangcai Fund has a significant holding in Sitaili, with its Xiangcai Medical Health Mixed A Fund increasing its stake by 473,300 shares, bringing the total to 659,300 shares, which represents 10.01% of the fund's net value [2] - The fund has achieved a year-to-date return of 43.27%, ranking 1631 out of 8148 in its category [2] - The fund manager, Zhang Quan, has been in charge for 1 year and 318 days, with the best return during his tenure being 66.19% [3]